ADX-629 + Placebo
Phase 1/2Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Ethanol Intoxication
Conditions
Ethanol Intoxication
Trial Timeline
Nov 15, 2021 → May 29, 2022
NCT ID
NCT05487404About ADX-629 + Placebo
ADX-629 + Placebo is a phase 1/2 stage product being developed by Aldeyra Therapeutics for Ethanol Intoxication. The current trial status is completed. This product is registered under clinical trial identifier NCT05487404. Target conditions include Ethanol Intoxication.
Hype Score Breakdown
Clinical
13
Activity
8
Company
2
Novelty
4
Community
3
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05392192 | Phase 2 | Completed |
| NCT05487404 | Phase 1/2 | Completed |
| NCT04847544 | Phase 2 | Completed |
| NCT04728711 | Phase 2 | Completed |
Competing Products
1 competing product in Ethanol Intoxication
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| tasimelteon + Ethanol + Placebo ethanol | Vanda Pharmaceuticals | Phase 1 | 25 |
Other Products from Aldeyra Therapeutics
Reproxalap Ophthalmic Solution (0.25%) QID + Vehicle Ophthalmic Solution QID + Reproxalap Ophthalmic Solution (0.25%) QID to BID + Vehicle Ophthalmic Solution QID to BIDPhase 3
69
Reproxalap Ophthalmic Solution (0.25%) + Reproxalap Ophthalmic Solution (0.5%) + Vehicle Ophthalmic SolutionPhase 3
69
Reproxalap Ophthalmic Solution (0.25%) + Vehicle Ophthalmic SolutionPhase 3
69
Reproxalap Ophthalmic Solution (0.25%) + Vehicle Ophthalmic SolutionPhase 3
69
ADX-2191 (intravitreal methotrexate 0.8%)Phase 3
69